Overview

Esomeprazole Treatment Co-diagnosed Non Erosive Reflux Disease (NERD) and Chronic Gastritis Patients

Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
0
Participant gender:
All
Summary
To compare the symptom control rate between 8 weeks esomeprazole treatment regimen group and 2 weeks esomeprazole treatment regimen group in co-diagnosed NERD and chronic gastritis patients, as evaluated by GerdQ after 24 weeks maintenance treatment/follow up.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
AstraZeneca
Treatments:
Esomeprazole
Criteria
Inclusion Criteria:

- Heartburn and/or regurgitation symptoms last for at least 3 months

- Endoscopic diagnosed as chronic gastritis (non-atrophic, and mild atrophic gastritis)
within 2 weeks prior to randomization GerdQ score =8

Exclusion Criteria:

- Endoscopic visible reflux esophagitis, esophageal varices, Barrett's esophagus,
malignancy or peptic ulcer Patients with Hp positive result and are eager to take Hp
eradication therapy will be excluded

- If Hp positive, patients could take Hp eradication therapy after the study completion
Previous PPI or H2RA therapy in the last 2 weeks before enrollment